Related Experiment Video
Updated: Oct 17, 2025

Genome-wide Analysis using ChIP to Identify Isoform-specific Gene Targets
Published on: July 7, 2010
Transcription Factor RBPJL Is Able to Repress Notch Target Gene Expression but Is Non-Responsive to Notch Activation
Leiling Pan1, Philipp Hoffmeister1, Aleksandra Turkiewicz2
1Center for Internal Medicine, Department of Internal Medicine I, University Medical Center Ulm, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Abstract:
The Notch signaling pathway is an evolutionary conserved signal transduction cascade present in almost all tissues and is required for embryonic and postnatal development, as well as for stem cell maintenance, but it is also implicated in tumorigenesis including pancreatic cancer and leukemia. The transcription factor RBPJ forms a coactivator complex in the presence of a Notch signal, whereas it represses Notch target genes in the absence of a Notch stimulus. In the pancreas, a specific paralog of RBPJ, called RBPJL, is expressed and found as part of the heterotrimeric PTF1-complex. However, the function of RBPJL in Notch signaling remains elusive. Using molecular modeling, biochemical and functional assays, as well as single-molecule time-lapse imaging, we show that RBPJL and RBPJ, despite limited sequence homology, possess a high degree of structural similarity. RBPJL is specifically expressed in the exocrine pancreas, whereas it is mostly undetectable in pancreatic tumour cell lines. Importantly, RBPJL is not able to interact with Notch-1 to -4 and it does not support Notch-mediated transactivation. However, RBPJL can bind to canonical RBPJ DNA elements and shows migration dynamics comparable to that of RBPJ in the nuclei of living cells. Importantly, RBPJL is able to interact with SHARP/SPEN, the central corepressor of the Notch pathway. In line with this, RBPJL is able to fully reconstitute transcriptional repression at Notch target genes in cells lacking RBPJ. Together, RBPJL can act as an antagonist of RBPJ, which renders cells unresponsive to the activation of Notch.
Insights
RBPJL, a pancreatic protein, acts as a Notch signaling antagonist. It binds DNA and represses genes, unlike RBPJ, offering new insights into Notch pathway regulation in pancreatic cancer.
Area of Science:
- Cellular biology
- Molecular biology
- Biochemistry
Background:
- The Notch signaling pathway is crucial for development and stem cell maintenance, but also implicated in cancers like pancreatic cancer.
- RBPJ is a key transcription factor in Notch signaling, acting as a coactivator or repressor.
- RBPJL, a pancreas-specific paralog of RBPJ, is part of the PTF1-complex, but its role in Notch signaling is unknown.
Purpose of the Study:
- To elucidate the function of RBPJL in the Notch signaling pathway.
- To investigate the structural and functional relationship between RBPJL and RBPJ.
- To determine RBPJL's role in pancreatic development and cancer.
Main Methods:
- Molecular modeling
- Biochemical assays
- Functional assays
- Single-molecule time-lapse imaging
Main Results:
- RBPJL shares structural similarity with RBPJ but is specifically expressed in the exocrine pancreas.
- RBPJL does not interact with Notch receptors (Notch-1 to -4) or support Notch-mediated transactivation.
- RBPJL binds RBPJ DNA elements, interacts with the Notch corepressor SHARP/SPEN, and can repress Notch target genes in RBPJ-deficient cells.
Conclusions:
- RBPJL functions as an antagonist of RBPJ in the Notch signaling pathway.
- RBPJL's antagonistic activity renders cells unresponsive to Notch activation.
- RBPJL's distinct role suggests potential therapeutic strategies for pancreatic cancer by modulating Notch signaling.
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
General Transcription Factors

